Ferring’s European Marketing Authorisation Application for controlled release misoprostol vaginal delivery system for the induction of labour accepted for review
-Ferring Pharmaceuticals announced today that it has received confirmation from European health authorities that the Marketing Authorisation…
Ferring Announces FDA Acceptance of NDA Filing for Controlled Release Misoprostol Vaginal Insert for Decreasing Time to Vaginal Delivery in Women
-Ferring Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA)…
New study showed desmopressin melt reduced sleep disruption in bedwetting children
-Preliminary results from a new, prospective study presented today at the first Joint Congress of the International Children’s Continence…
Fonds de solidarité FTQ, CTI Life Sciences Fund and Ferring Pharmaceuticals Create a New Biotech in Québec
-The Fonds de solidarité FTQ (the “Fonds”), CTI Life Sciences Fund and Ferring Pharmaceuticals are pleased to announce…
FDA approves Ferring’s PREPOPIK™ (sodium picosulfate, magnesium oxide, and anhydrous citric acid) for colonoscopy prep
-The U.S. Food and Drug Administration (FDA) granted Ferring Pharmaceuticals Inc. approval to market PREPOPIK (sodium picosulfate, magnesium…
